Palleon Pharmaceuticals has dosed the first subject in the randomised Phase II trial of E-602 (HLX79), a first-in-class human ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), headquartered in Massachusetts, is a global biopharmaceutical enterprise ...

The path forward lies in a three-pronged approach: prevention, early diagnosis, and improving transplant access ...

Changes in urine colour can signal kidney issues, with dark brown, red, or foamy urine indicating potential problems like ...

Cranberry tea is not just refreshing on the palate but also a super healthy beverage for your kidneys. According to experts, ...

President Ferdinand Marcos Jr. met with Asia’s “largest dialysis network” to explore deeper collaboration in advancing ...

Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has solidified its ...

Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.

Notable Drug Approvals.

The FDA approved multiple groundbreaking treatments in July, enhancing options across patient populations. The FDA maintained its momentum in July, issuing a wave of drug approvals across diverse ...